News | March 26, 2012

Study Shows Elective Use of IABP During High-Risk PCI Reduces Mortality

March 26, 2012 — Maquet announced positive long-term mortality results from the Balloon Pump-Assisted Coronary Intervention Study (BCIS-1), which evaluated the effect on major complications and mortality of elective use of an intra-aortic balloon pump (IABP) in patients with low ejection fraction undergoing high-risk percutaneous coronary intervention (PCI). Results from five years of follow-up showed that elective IABP use during PCI was associated with a 34 percent reduction in all-cause mortality, a significantly lower rate than in patients who had no planned IABP insertion prior to PCI. The long-term data were presented in an oral session at the American College of Cardiology (ACC) Annual Scientific Session in Chicago.

PCI in patients with impaired left ventricular function is associated with significant mortality and morbidity. These high-risk patients may not be able to withstand the consequences of ischemia or arrhythmias that may occur during PCI and thus are at risk of cardiogenic shock or death. In these circumstances, vital hemodynamic support can be provided by an IABP, which works by increasing coronary flow and reducing the oxygen demand of the heart. As such, IABPs have been shown to be beneficial in situations such as cardiogenic shock, where there is low blood pressure and poor heart function. The BCIS-1 study was the first randomized, controlled, multicenter trial to assess the efficacy and safety of elective IABP use in patients undergoing high-risk PCI.

“The BCIS-1 trial was a rigorously designed and conducted trial, and the long-term follow-up results are encouraging because they demonstrate that mortality following high-risk PCI can be reduced by elective insertion of an IABP,” said Divaka Perera, M.D., M.A., a co-investigator of the BCIS-1 trial, a consultant cardiologist at St. Thomas’ Hospital in London and a senior lecturer at King’s College London. “These five-year findings validate the prophylactic use of an IABP. These devices not only provide vital hemodynamic support for appropriate patients, but contribute to a long-term reduction in mortality.”

Perera, who presented the long-term data at ACC.2012, added, “The long-term BCIS-1 data demonstrate the clinical benefit of elective IABP support in patients who are hemodynamically stable but at high risk of complications during PCI. The use of elective IABP support is a frequent and common practice by interventionalists around the world, and these new long-term mortality data, which confirm the efficacy of elective IABP use, should justify an update of international guidelines to validate this real-world practice.”

BCIS-1 Trial Design and Results

The prospective, open, randomized, controlled, multicenter BCIS-1 trial randomized 301 high-risk patients to either elective IABP use and PCI or no planned IABP use and PCI, with rescue IABP permitted. All patients had severe left ventricular dysfunction (i.e., an ejection fraction of  less than 30 percent) and extensive coronary disease (i.e., a large amount of myocardium at risk). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE) at the time of hospital discharge or 28 days after PCI. The trial was conducted in 17 cardiac centers in the United Kingdom. The follow-up study involved collecting mortality data for all study participants for up to five years. The primary endpoint was all-cause mortality.

After five years of follow-up (median=51 months), elective IABP use during PCI was associated with a 34 percent reduction in all-cause mortality, a significantly lower rate than in patients who had no planned IABP insertion prior to PCI (p=0.039). Among patients who had elective IABP, 94 percent had procedural success, as did 93 percent of those with no planned IABP.

The BCIS-1 trial was sponsored by the British Cardiovascular Intervention Society, with unrestricted educational grants from Maquet Cardiovascular, Cordis and Johnson & Johnson.

For more information: www.maquet.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init